Prostate Cancer
Conditions
Interventions
Group 4 (PI-RADS >=4 points and tPSA <=10 ng/ml):None
Group 1 (PI-RADS = 3 points, abnormal tPSA, fPSA/tPSA, or PSAD):None
Group 2 (PI-RADS = 4 points and tPSA > 10 ng/ml):None
Group 3 (PI-RADS = 4 points and tPSA > 10 ng/ml):None
Sponsors
Shenzhen Hospital of Southern Medical University
Eligibility
Sex/Gender
Male
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1)Male, aged 50-80 years; 2)Suspicious lesions were found on mp MRI, with at least one lesion having a PI-RADS score =3, and abnormal tPSA and/or PSAD or f/t PSA; 3)Good compliance, able to communicate well with researchers; 4)Voluntarily participate in the study and sign the informed consent form
Exclusion criteria
Exclusion criteria: 1)Patients diagnosed with prostate cancer or acute prostatitis; 2)During the acute infection phase or in cases of urinary tract infection, researchers believe that a routine urine test has clinical significance; 3)Those who have undergone a prostate biopsy within one month; 4)Previously underwent prostate surgery, or received androgen deprivation therapy, radiotherapy, and chemotherapy; 5)In the decompensated stage of heart failure; 6)People with diseases that cause severe bleeding tendencies or those who take anticoagulants long-term and cannot stop taking them; 7)Severe internal hemorrhoids, external hemorrhoids, perianal or rectal lesions; 8)Patients with severe osteoarticular diseases who cannot assume the lithotomy position; 9)A hypertensive crisis; 10)Unable to undergo anesthesia; 11)Individuals with mental illness or mental disorders who cannot understand the informed consent form; 12)People who use electronic devices such as implanted pacemakers, cochlear implants, and nerve stimulators; 13)Other surgical contraindications, or individuals deemed unsuitable to participate in the trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive rate of prostate biopsy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive rates of prostate biopsy at different stratifications; | — |
Countries
China
Contacts
Public ContactWu Tao
Shenzhen Hospital of Southern Medical University
Outcome results
None listed